

10/0656830XSE9/1646

TRANSMITTAL LETTER (General - Patent Pending)	Docket No. 11373
---	---------------------

In Re Application Of: Tracy A. Willson, et al.
New Serial # 10036,568

Serial No. 10036,568	Filing Date June 29, 1998	Examiner Nirmal Singh Basi	Group Art Unit 1646
------------------------------------	------------------------------	-------------------------------	------------------------

Title:
A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

- PRELIMINARY AMENDMENT
- STATEMENT UNDER 37 C.F.R. 1.821(F)
- SUBSTITUTE PAPER COPY OF SEQUENCE LISTING
- SUBSTITUTE COMPUTER READABLE FORM OF SEQUENCE LISTING

in th above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
 - ☐ Charge the amount of _____
 - ☒ Credit any overpayment.
 - ☒ Charge any additional fee required.

RECEIVED
JUL 15 2003
TECH CENTER 1600/2900
PATENT & TRADEMARK OFFICE

Peter I. Bernstein
Signature

Dated: July 7, 2003

RECEIVED
JUL 15 2003
TECH CENTER 1600/2900

Peter I. Bernstein
Registration No. 43,497
SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343

I certify that this document and fee is being deposited on July 7, 2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Peter I. Bernstein
Signature of Person

Peter I. Bernstein

Typed or Printed Name of Person

PIB:dg
cc:

BEST AVAILABLE COPY



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Tracy A. Willson, et al.

Examiner: Unassigned

Serial No: 10/036,568

Art Unit: 1646

Filed: November 7, 2001

Docket: 11373Z

For: A NOVEL HAEMOPOIETIN RECEPTOR
AND GENETIC SEQUENCES ENCODING
SAME

Date: July 7, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

6/B
M.G.J.
7/28/03
RECEIVED
JUL 15 2003
TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Sir:

Applicants submit the following amendment for entry in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450 on July 7, 2003.

Dated: July 7, 2003


Peter I. Bernstein

IN THE SPECIFICATION:

Page 31, beginning at line 10, please amend the paragraph to read as follows:

BRIEF DESCRIPTION OF THE FIGURES BRIEF DESCRIPTION OF THE DRAWINGS

B¹
~~Figure 1 is a representation of~~ Figures 1A-1F show the nucleotide ({SEQ ID NO:1}) and predicted amino ({SEQ ID NO:2}) sequence of murine NR4. The untranslated region is shown in lower case and the translated region in upper case. The conventional one-letter code for amino acids is employed, potential asparagine linked glycosylation sites are underlined and the conserved cysteine residues and WSXWS (SEQ ID NO: 9) motif of haemopoietin receptor family members are shown in bold. The predicted signal sequence is underlined in bold while the transmembrane domain is underlined with dashes. The sequence shown is a composite derived from the analysis of 8 cDNA clones derived from 3 libraries. The 5'-end of the sequence (nucleotides -60 to 351) is derived from a single cDNA clone but is also present in genomic DNA clones that have been isolated. Boxed region – typical haemopoietin receptor domain, amino acids 118-340.

Page 31, beginning at line 27, please amend the paragraph to read as follows:

B²
~~Figure 3 is a graphical representation depicted~~ Figures 3A-3B depict saturation isotherms of ¹²⁵I-IL-13 and ¹²⁵I-IL-4 binding; saturation isotherms depicted as Scatchard plots of IL-4(°) and IL-13(•) binding to (A) COS cells expressing the IL-13Rα(NR4) (Figure 3A), (B) CTLL cells (Figure 3B) and (C) CTLL cells expressing the IL-13Rα(NR4) (Figure 3C). Data have been normalized to 1 x10⁴ COS cells and 1x10⁶ CTLL cells and binding was carried out on ice for 2 to 4 hours.

Page 32, beginning at line 3, please amend the paragraph to read as follows:

B3
~~Figure 4 is a graphical representation showing~~ Figures 4A-4D show specificity of IL-4 and IL-13 binding; the ability of IL-4(°) and IL-13(•) to compete for ¹²⁵I-IL-13 binding to (A) COS cells expressing the IL-13Rα(NR4) (Figure 4A) and (C) CTLL cells expressing the IL-13Rα (NR4) (Figure 4C) or to compete for ¹²⁵I-IL-4 binding to (B) CTLL cells (Figure 4) and (D) CTLL cells expressing the IL-13Rα(NR4) (Figure 4). Binding was carried out at 4°C for 2 to 4 hours and the data expressed as a percentage of the specific binding observed in the absence of a competitor (Δ).

Page 32, beginning at line 10, please amend the paragraph to read as follows:

B4
~~Figure 5 is a graphical representation showing~~ Figures 5A-5B show factor dependent proliferation of cells expressing NR4. Two hundred (A) CTLL cells (Figure 5) or (B) CTLL cells (Figure 5) expressing the IL-13Rα (NR4) were incubated in the absence of cytokine or with various concentrations of IL-2 (□), IL-4(°) or IL-13 (•). After 48 hours viable cells were counted and data were expressed as a percentage of the number of viable cells observed with a maximal concentration of IL-2.

Page 32, beginning at line 3, please amend the paragraph to read as follows:

B5
~~Figure 7 is a representation of~~ Figures 7A-7J show the nucleotide and corresponding amino acid sequence of murine SEQ ID NOS: 1 and 2, respectively) and human (SEQ ID NOS: 3 and 4, respectively) NR4 (IL-13Rα) genes. The nucleotide and predicted amino acid sequence of human (H) and murine (M) IL-13Rα(NR4) were aligned by eye, with gaps (-) inserted to optimize the alignment. The numbering is for the murine clone,

B5. nucleotides that form part of the coding region are shown in upper case, whilst those of the untranslated regions are shown in lower case. Amino acids identical between the predicted murine and human proteins are indicated by (*). DNA encoding the murine signal sequence is underlined, with A26 or T27 being the predicted first amino acid of the mature protein.

Page 33, beginning at line 12, please amend the paragraph to read as follows:

B6. Figure 10 is a representation of the N-terminal amino acid sequence of murine NR4 (SEQ ID NOS: 10 and 11).

Page 37, beginning at line 3, please amend the paragraph to read as follows:

A library was constructed λ ZAP II using *ApoI* digested genomic DNA from embryonal stem cells and screened with a pool of ^{32}P -labelled oligonucleotides encoding the amino acid sequence Trp-Ser-Asp-Trp-Ser (SEQ ID NO: 12) found in many members of the haemopoietin receptor family. One hybridising bacteriophage clone was found to contain a sequence that appeared to encode part of a novel member of the haemopoietin receptor family.

B7. This receptor was given the operational name NR4. The sequence of the genomic clone was used to isolate cDNAs encoding NR4 from WEHI-3B cell, peritoneal macrophage, bone marrow, skin and kidney libraries. A composite of the nucleotide sequence (SEQ ID NO: 1) and predicted amino acid sequence (SEQ ID NO: 2) of these cDNAs is shown in Figure 1.

The NR4 cDNA is predicted to encode for a protein of 424 amino acid residues, containing a putative signal sequence and transmembrane domain. The extracellular region of the protein contained an immunoglobulin-like domain (amino acids 27-117), in addition to a typical haemopoietin receptor domain (amino acids 118-340) which includes four conserved cysteine

residues and the characteristic Trp-Ser-Asp-Trp-Ser motif (Figure; in bold as **WSXWS**). The cytoplasmic tail of the new receptor was 60 amino acids in length.
